New antibody trial aims to block severe COVID-19
NCT ID NCT07445971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing an experimental antibody called MDX2301 to see if it can help prevent severe COVID-19 in healthy adults and those at higher risk. About 80 participants will receive either the antibody or a placebo, given as an injection or infusion. The main goal is to check safety and how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MDX2301 (an experimental antibody)
What this could lead to
If successful, this could lead to a new antibody-based prevention for severe COVID-19, especially for people at higher risk.
What could go wrong
This is a very early Phase 1 study with only 80 participants, so safety and effectiveness are not yet proven. The results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TrialMed Clinical Research Unit
RECRUITINGLas Vegas, Nevada, 89113, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
TrialMed Clinical Research Unit
RECRUITINGAustin, Texas, 78744, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••